Acorda Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Acorda Therapeutics, Inc.
"Otsuka is very, very committed to nutraceuticals generally, and supplements specifically,” says Pharmavite CEO Jeff Boutelle.
Although the spread of HIV/AIDS appears to be largely under control in China, increasing infections among the elderly are causing concern due to a range of risk factors, while domestic firms move to expand their drug offerings.
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks. Last week, cardiologists got new guidelines for managing patients with atrial fibrillation and Nevro made a big move to expand beyond its core spinal cord stimulation business.
With the only FDA-approved treatment off the market, the FDA is looking for ideas for development of new preterm birth treatments.
- Drug Delivery
- Other Names / Subsidiaries
- Neuronex, Inc.
- Civitas Therapeutics
- Biotie Therapies Corp.
- Elbion GmbH
- Synosia Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.